VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: biowa who wrote (3869)	1/6/1998 8:04:00 PM
From: Biomaven	Read Replies (1) of 9719

biowa: From PCYC's just-filed S-3: ATHEROSCLEROSIS THERAPY ANTRIN for Photoangioplasty of Atherosclerosis Preclinical studies conducted by the Company and its collaborators have demonstrated that texaphyrins also localize to atherosclerotic plaque. Preclinical studies have also indicated that following intravenous administration of ANTRIN, the Company's lutetium texaphyrin drug, intravascular exposure of atherosclerotic plaque to 732-nanometer light delivered through a catheter resulted in elimination of the plaque without damage to the endothelium using a technique which the Company refers to as photoangioplasty. The Company believes that these results suggest that photoangioplasty of atherosclerosis with ANTRIN has the potential to eliminate or reduce plaque without complications such as thrombosis and restenosis. Additional preclinical studies further indicated that photoangioplasty of atherosclerosis with ANTRIN could be used to treat diffuse atherosclerosis over long segments of blood vessels, which is not possible with other currently available techniques. ANTRIN's selective localization in plaque and relatively rapid clearance from blood may provide advantages for its application in the treatment of atherosclerosis. The Company also believes that photoangioplasty with ANTRIN has potential use in peripheral vascular disease, coronary artery disease and in the treatment of restenosis. The Company recently initiated a Phase I clinical trial at Stanford University Medical Center for the use of ANTRIN in the photoangioplasty of peripheral vascular disease. This Phase I dose-escalation trial will enroll up to 30 patients to assess the safety of ANTRIN. ___________ The company didn't actually make an announcement that the trials had started, but had previously said they would commence before the end of 1997. This remains my second-favorite stock (after SEPR). The two of them make up about 60% of my portfolio - I wish it had been a full 100% (sigh). While they did well in '97, my view is that both SEPR and PCYC still have a lot of appreciation ahead of them over the next 2-3 years. Peter (still licking his DEPO wounds).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next